Table 2 Risk of prostate cancer death by anti-epileptic drug use.
Risk of prostate cancer death | |||||||
|---|---|---|---|---|---|---|---|
AED use before diagnosis | AED use after diagnosis | ||||||
Number of PCa deaths/PCa cases | HR (95% CI)age adjusted | \({{{{{\mathbf{HR}}}}}} ({{{{{\mathbf{95\%}}}}}} {{{{{\mathbf{CI}}}}}})_{{{{{{\mathbf{multivariable}}}}}}\; {{{{{\mathbf{adjusted}}}}}}^{\mathbf a}}\) | Number of PCa deaths/PCa cases | HR (95% CI)age adjusted | \({{{{{\mathbf{HR}}}}}} ({{{{{\mathbf{95\%}}}}}} {{{{{\mathbf{CI}}}}}})_{{{{{{\mathbf{multivariable}}}}}}\; {{{{{\mathbf{adjusted}}}}}}^{\mathbf a}}\) | ||
No AED use | 883/8965 | Ref. | Ref. | No AED use | 861/8665 | Ref. | Ref. |
Ever use of AEDs | 37/296 | 1.71 (1.23–2.38) | 1.39 (0.98–1.99) | Ever use of AEDs | 59/596 | 1.72 (1.21–2.43) | 1.42 (1.00–2.03) |
Intensity of usage (DDDs per year) | |||||||
1st tertile | 10/103 | 1.30 (0.70–2.42) | 1.92 (1.02–3.59) | 1st tertile | 21/183 | 4.39 (2.42–7.96) | 4.52 (2.48–8.20) |
2nd tertile | 12/94 | 1.64 (0.93–2.90) | 0.87 (0.45–1.67) | 2nd tertile | 22/216 | 1.76 (0.94–3.28) | 1.22 (0.63–2.35) |
3rd tertile | 15/99 | 2.27 (1.36–3.78) | 1.77 (1.02–3.08) | 3rd tertile | 16/197 | 1.09 (0.62–1.92) | 0.95 (0.54–1.68) |
P for trend by tertile | 0.002 | 0.085 | P for trend by tertile | 0.09 | 0.45 | ||
